BIONEER CORPORATION

Bioneer Leads Innovation in Gene Synthesis with Development of 100kb-Scale DNA Synthesis Technology

Bioneer, a leading biotechnology company with over 30 years of expertise in molecular and synthetic biology, announced on May 26 that it has developed a new gene synthesis technology capable of precisely synthesizing and assembling DNA sequences up to 100 kilobases (100kb) in length.

This breakthrough technology focuses on accurately synthesizing up to 100,000 base pairs of DNA from short oligonucleotides and assembling them into long, continuous sequences. It is expected to open new frontiers in high-throughput gene synthesis and complex genome design.

The 100kb DNA synthesis technology is built on Bioneer’s proprietary high-efficiency platform, which leverages internally produced key raw materials to ensure both high quality and cost competitiveness. With this advancement, Bioneer is now equipped to offer groundbreaking solutions for large-scale genome projects and synthetic biology researchers working with intricate DNA constructs.

Alongside the development of this new technology, Bioneer has also enhanced its advanced synthesis capabilities and services. Its proprietary oligo design technology, which boasts an initial fragment assembly success rate of over 99%, overcomes concentration variation challenges during synthesis and maximizes small-fragment assembly efficiency. This innovation also supports the development of a fully automated gene synthesis process utilizing artificial intelligence, aiming to establish a system capable of producing thousands of initial fragments with minimal human intervention.

To synthesize DNA structures of up to 100kb, Bioneer employs a combination of advanced techniques, including Gibson Assembly, its own proprietary fragment assembly methods, and in vivo assembly. Multiple fragments can be assembled simultaneously with high efficiency. The final synthesized genes are verified with 100% accuracy through single-colony Sanger sequencing, and a range of additional services is offered, such as custom vector cloning and mRNA synthesis.

Through the launch of its 100kb DNA synthesis technology, Bioneer aims to meet the diverse needs of researchers in academia, biotechnology, and the pharmaceutical industry worldwide, reinforcing its leadership in synthetic biology innovation. According to a 2024 report by global market research firm Data Bridge Market Research, the global gene synthesis market is valued at USD 3.25 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 22.9% from 2025 to 2032.

A company representative stated, “The development of this 100kb synthesis technology marks a significant milestone in our efforts to help researchers handle larger and more complex genetic information quickly and cost-effectively. The ability to accurately synthesize numerous short DNA fragments and assemble them into long, desired sequences will greatly expand the potential of synthetic biology.” ###